Background/objectives: Increased endogenous glucose production is a hallmark of type 2 diabetes. Evidence from animal models has suggested that a likely cause of this is increased mRNA expression of glucose 6-phosphatase and phosphoenolpyruvate carboxykinase (encoded by G6PC, PCK1 and PCK2). But another contributing factor may be decreased liver glucokinase (encoded by GCK). Methods: We examined expression of these enzymes in liver biopsies from 12 nondiabetic and 28 diabetic individuals. Diabetic patients were further separated into those with HbA1c lower or higher than 7.0. Results: In diabetic subjects with HbA1c > 7.0, we found that gluconeogenic enzymes were expressed normally, but GCK was suppressed more than 60%. Moreover, HbA1c and fasting glucose were negatively correlated with GCK, but showed no correlation with G6PC, PCK1, or PCK2. Conclusion: These findings suggest an underlying dysregulation of hepatic GCK expression during frank diabetes, which has implications for the therapeutic use of glucokinase activators in this population.
INTRODUCTION
A characteristic feature of type 2 diabetes is increased endogenous glucose production, largely due to increased hepatic glucose production (HGP) [1e4] . Two rate-limiting enzymes of HGP are glucose 6-phosphatase catalytic subunit (encoded by G6PC) and phosphoenolpyruvate carboxykinase (encoded by PCK1 and PCK2). As the expression of these enzymes is suppressed by insulin, it has been widely held that patients with type 2 diabetes (T2D) would have increased expression of G6PC and PCK, due to hepatic insulin resistance. However, it has been challenging to correlate expression of these enzymes with diabetes or glycemia in humans [5, 6] . Another determinant of hepatic glucose homeostasis is glucokinase (encoded by GCK). G6PC and GCK act in opposition to regulate the intracellular levels of free glucose; thus, the coordinated regulation of these two enzymes ultimately determines the gradient and flux of glucose into or out of the hepatocyte [7] . An increased ratio of G6PC/ GCK, as occurs during fasting, causes glucose efflux to the bloodstream, whereas a decreased ratio causes increased influx. Previous work has indicated that GCK activity is decreased in type 2 diabetes [8e12]. Although mutations in the GCK gene cause maturity onset diabetes of the young type 2 (MODY2), GCK mutations are not found in the etiology of classical T2D. Thus, the decrease in GCK activity is likely due to transcriptional or posttranslational effects. However, the expression of liver GCK during T2D has not yet been established.
In this study, we investigated the contribution of GCK, G6PC, and PCK expression to glycemia in diabetes. We examined liver tissue from 40 obese subjects: 12 had normal glucose tolerance (NGT) and 28 had type 2 diabetes.
MATERIALS AND METHODS

Subjects and liver biopsies
A liver biopsy was obtained during surgery in 28 type 2 diabetic and 12 nondiabetic subjects undergoing bariaric surgery. The liver samples were collected in RNA-Later (Ambion Inc., Applied Biosystems, Austin, TX, USA), and stored at À20 C for total RNA extraction. Before surgery in each subject, after an overnight (12e14 h) fast, peripheral blood samples were obtained for determination of the routine blood chemistry plasma glucose, insulin and HbA 1c concentrations. The diabetic patients were asked to discontinue oral antidiabetic agents (metformin AE sulfonylureas) 48e72 h before the study. The protocol was approved by the local ethics committee. The nature and purpose of the study were carefully explained to all participants before they provided written consent to participate.
Analytical procedures
Plasma glucose was measured by the glucose-oxidase technique (Analox GM-9), plasma insulin by electro-chemiluminescence (on a COBAS e411 instrument, Roche, Indianapolis, USA).
Gene expression
RNA was extracted using Trizol (Life Technologies), cDNA was synthesized using reverse transcriptase (Applied Biosystems), and quantitative PCR was performed using SyBr Green (BioRad).
Statistical analyses
Data are given as mean AE SEM or median and [interquartile range]. Group differences were analyzed by Kruskall-Wallis and Manne Whitney tests. P value <0.05 was considered statistically significant.
RESULTS
Patient characteristics
The anthropomorphic and metabolic characteristics of the patients are shown in Table 1 . T2D patients for whom HbA 1c was available were further separated into two groups, those with HbA 1c <7.0% (53 mmol/ mol), and those >7.0%. Diabetic patients were older than NGT subjects, and the high HbA 1c group had lower average BMI than the other two groups.
Glucokinase expression is reduced in T2D
In T2D patients overall, we identified a 43% reduction in GCK expression relative to NGT (0.57 AE 0.09 vs 1.00 AE 0.17, p ¼ 0.028). However, we saw no change in expression of G6PC, PCK1, or PCK2 (data not shown). When diabetic subjects were subdivided into HbA 1c categories, we found that the high HbA 1c group showed a substantial reduction in GCK compared to the NGT or low HbA 1c groups ( Figure 1A ). There were no significant changes in G6PC, PCK1, or PCK2 expression among the three groups ( Figure 1A ). We also examined the glucose 6-phosphate transporter (encoded by SLC37A4), which was also not different between groups ( Figure 1A ).
Glucokinase expression is negatively correlated with HbA 1c
Next we examined the association of gene expression with measures of glycemia. We found that GCK was significantly negatively correlated with HbA 1c and fasting glucose (Figure 1BeC ). In contrast, G6PC, PCK1, PCK2, and SLC37A4 were not associated with HbA 1c (Figure 1DeG ) or fasting glucose (data not shown). Overall, these data suggest that progressive worsening of glycemia in type 2 diabetes is significantly associated with suppression of GCK, but not with expression of other gluconeogenic enzymes.
DISCUSSION
This study aimed to investigate contributors to the increase in HGP during diabetes. Consistent with prior reports, we find that liver expression of gluconeogenic enzymes alone cannot explain this phenotype [5, 6] . On the other hand, our data indicate that suppression of hepatic GCK in diabetes patients: (i) explains the decreased GCK activity observed in previous studies [8e12], and (ii) contributes to hyperglycemia quantitatively. The fact that defective hepatic GCK is sufficient to impair glycogen synthesis and increase gluconeogenesis was previously established in studies of liver metabolism in MODY2 patients [13] . Moreover, it has been shown that restoration of hepatic GCK activity in Zucker diabetic fatty rats causes normalization of plasma glucose and suppression of endogenous glucose production [14] . GCK is regulated by posttranslational and transcriptional mechanisms [7] . Posttranslational regulation by glucose occurs through the glucokinase regulatory protein, which binds to GCK and causes its nuclear sequestration and protein stabilization. Dissociation of the two proteins occurs at high glucose concentrations, causing cytoplasmic translocation and accelerated degradation of GCK [7, 15] . One of the limitations of our study was the lack of sufficient tissue to perform immunoblots. However, we found compelling evidence that frank diabetes is associated with a disruption in the transcriptional control of GCK, which is carried out by insulin [16] . Major mediators of insulin's effect on GCK are the FOXO transcription factors. FOXOs are known for their role in promoting HGP during fasting [17] . Under normal conditions, FOXOs are inactivated by insulin, through AKTmediated phosphorylation and nuclear exclusion. Thus, a widely held explanation for excessive glucose production during diabetes is inappropriate activation of the hepatic FOXO pathway, due to insulin resistance. Two critical aspects of how FOXO promotes glucose production are by promoting G6PC [17] and suppressing GCK [18e 21]. This suggests that activated FOXOs may be responsible for excessive GCK suppression in diabetes. Consistent with this possibility, FOXO target IGFBP1 was significantly elevated in the high HbA 1c patients (data not shown). How, then, can we reconcile the fact that G6PC was not also elevated? One possible explanation is that FOXOs' effect on GCK is more potent than its effect on G6PC, as we have previously observed in mice [21] . It is also possible that posttranslational modifications of FOXO that are induced by hyperglycemia, such as acetylation, affect some targets more than others [22, 23] . In addition to its role in glucose homeostasis, hepatic GCK also plays a critical role in promoting de novo lipogenesis (DNL), a fact that has hindered the development of glucokinase activators as diabetes therapy [24] . Indeed, previous work has shown that liver GCK expression is positively associated with liver triglyceride content and a marker of DNL in humans [25] . Based on these findings, suppression of GCK e as we observed in our severely diabetic patients e might be expected to reduce lipogenic flux. This may seem paradoxical, as diabetic patients typically demonstrate hypertriglyceridemia. However, we observed no correlation of GCK to plasma triglyceride levels in our subjects (data not shown). A potential explanation is that DNL contributes to only a portion of circulating triglyceride levels [26e28], the major fraction originating from reesterification of free fatty acids; the latter substrate circulates in increased amounts in type 2 diabetic patients due to insulin resistance of lipolysis [29, 30] . There has been a long-standing interest in developing antidiabetic glucokinase activators [24] . Given the narrow therapeutic window of these molecules, it may be important to increase our understanding of GCK dysregulation in the progression of T2D. This may be particularly valuable in designing individualized therapeutic regimens [4] . Brief communication
